Details for Patent: 7,683,054

Title:	Galenic formulations of organic compounds
Abstract:	The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s):	Rigassi-Dietrich; Petra Gisela (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee:	Novartis AG (Basel, CH)
Filing Date:	Apr 29, 2005
Application Number:	11/119,273
Claims:	1. A solid oral dosage form comprising aliskiren hemi-fumarate salt present in an amount of about 663 mg per dosage, said dosage form providing a mean maximum plasma concentration of aliskiren of about 420 ng/mL a median of about 2 hours after administration of a single dosage. 2. A solid oral dosage form comprising aliskiren hemi-fumarate salt present in an amount of about 663 mg per dosage, said dosage form providing a mean AUC.sub.0-96 of aliskiren of about 3240 ng h/mL after administration of a single dosage. 3. A solid oral dosage form comprising about 663 mg of aliskiren in the form of a hemi-fumarate salt, and a carrier medium, said dosage form providing a mean maximum plasma concentration of aliskiren within the range of 80% to 120% of about 420 ng/mL a median of about 2 hours after administration of a single dosage, whereby a mean AUC.sub.0-96 of aliskiren is within the range of 80% to 120% of about 3240 ngh/mL.